PMV Pharma Finalizes $50.8M Offering with NDA-Linked Warrant Reset Terms
PMVP sits 25% above its 52-week low of $1.02 on elevated volume (17× avg).
Summary
PMV Pharma finalized a $50.8 million offering at $1.21 per share with warrants that reset to a lower exercise price upon FDA NDA acceptance, extending cash runway into Q1 2028 amid a going concern warning.
Key Events · Financing and Capital Events · PMVP
-
Offering Priced at $1.21 Per Share
22,055,000 shares at $1.21, 19,900,000 pre-funded warrants at $1.20999, and 41,955,000 common stock warrants at $1.21 exercise price, for total gross proceeds of $50,765,351.
-
Net Proceeds of $47.0 Million
After underwriting discounts of $3,045,933 (6% of offering price) and estimated expenses of $705,280, net proceeds are approximately $47.0 million, extending cash runway into Q1 2028.
-
NDA-Linked Warrant Reset Provision
Upon FDA NDA acceptance announcement, warrant exercise price resets to the greater of 33% of $1.21 or the 5-day VWAP after announcement, with share count adjusted to preserve aggregate exercise value.
-
Mandatory Exercise on Positive NDA
If FDA accepts the NDA, PMV can force exercise of up to 50% of warrants between days 30-60 after the announcement, with unexercised warrants becoming void.
Analysis · PMVP · Life Sciences
PMV Pharmaceuticals finalized a $50.8 million public offering priced at $1.21 per share — a steep discount to the $1.27 price at the time of this report — with warrants carrying an unusual NDA-linked exercise price reset. The company faces a going concern warning with cash runway under one year, so this capital raise is critical for survival. The warrant terms are aggressive: if the FDA accepts the NDA for rezatapopt, the exercise price drops to the greater of 33% of $1.21 or the 5-day VWAP after the announcement, and the company can force exercise of up to 50% of warrants. This structure could significantly increase dilution if the NDA is accepted, but also provides a mechanism to raise additional capital on positive news. The offering extends cash runway into Q1 2028, addressing the near-term liquidity crisis.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.9% of the 1612 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMVP was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69M. The 52-week trading range was $1.02 to $1.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.